Insights
Insights From Our Experts
Articles
Can Direct‑to‑Employer Models Redefine Access to Obesity Care?
As demand for GLP‑1 therapies continues to rise, employers are facing increasing pressure to balance affordability, access, and outcomes. What was once a benefits challenge has quickly become a core strategic issue — influencing talent retention,…
Views from Asembia: What Pharma Leaders Are Prioritizing Now
Insights from Krista Pinto on access, AI, and the shift to integrated commercialization Following Asembia 2026, a clear picture is emerging of what matters most to pharmaceutical leaders today. In a recent interview with pharmaphorum, Krista Pinto, a commercialization expert at EVERSANA,…
How MFN is Reshaping Global Drug Pricing – and How NAVLIN Insights Tracks It
Nearly a year after the executive order to implement Most Favored Nation (MFN) drug pricing policy in the U.S., clear strategic pictures are emerging, including: Launch prices in Europe that are higher than launch prices in the U.S. Prices in Japan that are 90-100% lower than the U.S. Longer launch timelines outside…
How Pharma Can Scale Innovation Without Losing Executional Rigor
As the commercialization landscape grows more complex, pharmaceutical manufacturers are being challenged to scale innovation while maintaining executional rigor. Rising expectations around access, data integration, and AI adoption are forcing organizations to rethink how they operate across the product lifecycle. …
Predicting PICOs Under EU Joint Clinical Assessment: Is One Method Enough?
The European Union’s new Joint Clinical Assessment (JCA) framework is set to revolutionize market access, but it also introduces a new layer of complexity. With a single clinical assessment informing reimbursement decisions across all member states, the stakes…
Winners Circle Podcast: How EVERSANA Built an 80/20 AI Model That Works
In a Winners Podcast episode, Faruk Capan, Chief Innovation Officer at EVERSANA, discusses how AI can transform pharmaceutical marketing — without compromising compliance. Pharmaceutical marketing operates under constraints most industries never face. Every claim must be compliant,…
Medical Affairs Under Pressure: A Modern Operating Model for the Next Era
Posted by
Samie Ahmed, PharmD, MS , Michael DeLuca, PharmD, MBA, MSRA , Mary Mehrabian, PharmD, BCGP, BCMAS on April 29, 20264/29/26
Medical Affairs is facing sustained structural and operational complexity. As its strategic role expands across the product lifecycle, Medical Affairs is expected to deliver launch excellence, shape evidence strategy, generate actionable insights, and demonstrate measurable organizational…
The Future of Pharmaceutical Deployment
The ground is shifting beneath the feet of the pharmaceutical industry. The long-standing formula for commercial success used to include building massive, dedicated sales forces. Now, it has become a liability in an era of patent cliffs, cost…
You Can Build AI In House.
But Should You?
AI is no longer an experiment in pharma. It is an executive mandate tied to growth, efficiency and competitive advantage. Most large pharmaceutical organizations have already committed to investing. The harder question is how to translate…
The Strategic Advantage: Why a Vendor-Neutral Approach is Key to PV Success
When implementing a new pharmacovigilance system, the greatest threat isn’t a technical glitch, but the inherent bias that comes with a vendor-led solution. This subtle conflict of interest often results in a system designed for the vendor’s benefit,…